<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02797210</url>
  </required_header>
  <id_info>
    <org_study_id>16-5094</org_study_id>
    <nct_id>NCT02797210</nct_id>
  </id_info>
  <brief_title>Examining the Efficacy of Orbitofrontal Cortex rTMS for Depression</brief_title>
  <acronym>OFC-rTMS</acronym>
  <official_title>Efficacy of Orbital Frontal Cortex Repetitive Transcranial Magnetic Stimulation Magnetic Stimulation in the Treatment of Refractory Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will compare the efficacy of active inhibitory OFC-rTMS to sham OFC-rTMS in major
      depression. The trial will include structural and functional MRI, EEG, and behavioral
      measures obtained before, during, and after treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>17-Item Hamilton Rating Scale for Depression (HAMD-17)</measure>
    <time_frame>Baseline, after each week of treatment (i.e. after 5 days of treatment) and at 1, 4, and 12 weeks post-treatment.</time_frame>
    <description>Outcome measured by a change in HAMD-17 score from baseline to 2 weeks post-treatment. A 50% improvement in the score is considered a response to rTMS. A final score of &lt;8 is categorized as remission.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory-II (BDI-II)</measure>
    <time_frame>Daily for 6 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>1 week pre- and 1 week post-treatment</time_frame>
    <description>10 min resting-state functional MRI (rs-fMRI) at 3 Tesla (3T)</description>
  </other_outcome>
  <other_outcome>
    <measure>Electroencephalography (EEG)</measure>
    <time_frame>Day 1 (First day of treatment), Day 15, and Day 30 (Final day of treatment)]</time_frame>
    <description>10 min resting-state and task-based (response inhibition, reward sensitivity) acquisitions</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Sham then Active Stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sham repetitive transcranial magnetic stimulation (rTMS) to right orbitofrontal cortex, twice daily, 5 days per week for 3 weeks, then active rTMS to right orbitofrontal cortex, twice daily, 5 days per week for 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active then Sham Stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active repetitive transcranial magnetic stimulation (rTMS) to right orbitofrontal cortex, twice daily, 5 days per week for 3 weeks, then sham rTMS to right orbitofrontal cortex, twice daily, 5 days per week for 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous theta-burst stimulation</intervention_name>
    <arm_group_label>Sham then Active Stimulation</arm_group_label>
    <arm_group_label>Active then Sham Stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. are outpatients

          2. are voluntary and competent to consent to treatment

          3. have a Mini-International Neuropsychiatric Interview (MINI) confirmed diagnosis of
             major depressive disorder (MDD), single or recurrent

          4. are between the ages of 18 and 65

          5. have failed to achieve a clinical response to an adequate dose of an antidepressant
             based on an Antidepressant Treatment History Form (ATHF) score of &gt; 3 in the current

          6. have a score &gt; 18 on the HAMD-17

          7. have had no increase or initiation of any psychotropic medication in the 4 weeks prior
             to screening

          8. able to adhere to the treatment schedule

          9. Pass the TMS adult safety-screening (TASS) questionnaire

         10. have normal thyroid functioning based on pre-study blood work.

        Exclusion Criteria:

          1. have a MINI-International Neuropsychiatric (MINI) confirmed diagnosis of substance
             dependence or abuse within the last 3 months

          2. have a concomitant major unstable medical illness, cardiac pacemaker or implanted
             medication pump

          3. have active suicidal intent

          4. are pregnant

          5. have a lifetime Mini-International Neuropsychiatric Interview (MINI) diagnosis of
             bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform
             disorder, delusional disorder, or current psychotic symptoms

          6. have a MINI diagnosis of obsessive compulsive disorder, post-traumatic stress disorder
             (current or within the last year), anxiety disorder (generalized anxiety disorder,
             social anxiety disorder, panic disorder), or dysthymia, assessed by a study
             investigator to be primary and causing greater impairment than MDD

          7. have a diagnosis of any personality disorder, and assessed by a study investigator to
             be primary and causing greater impairment than MDD

          8. have failed a course of electroconvulsive therapy (ECT) in the current episode or
             previous episode

          9. have any significant neurological disorder or insult including, but not limited to:
             any condition likely to be associated with increased intracranial pressure, space
             occupying brain lesion, any history of seizure except those therapeutically induced by
             ECT, cerebral aneurysm, Parkinson's disease, Huntington's chorea, multiple sclerosis,
             significant head trauma with loss of consciousness for greater than or equal to 5
             minutes

         10. have an intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear
             implants, or electrodes) or any other metal object within or near the head, excluding
             the mouth, that cannot be safely removed

         11. if participating in psychotherapy, must have been in stable treatment for at least 3
             months prior to entry into the study, with no anticipation of change in the frequency
             of therapeutic sessions, or the therapeutic focus over the duration of the study

         12. clinically significant laboratory abnormality, in the opinion of the study
             investigator

         13. currently (or in the last 4 weeks) take more than lorazepam 2 mg daily (or equivalent)
             or any dose of an anticonvulsant due to the potential to limit rTMS efficacy

         14. non-correctable clinically significant sensory impairment (i.e., cannot hear well
             enough to cooperate with interview).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UHN MRI-Guided rTMS Clinic, Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2016</study_first_submitted>
  <study_first_submitted_qc>June 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2016</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

